id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-300774-5mrkmctl	Hernández-Mora, Miguel Górgolas	Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia	2020-10-25		.txt	text/plain	4340	230	50	INTRODUCTION: Tocilizumab is an interleukin 6 receptor antagonist which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), aiming to ameliorate the cytokine release syndrome (CRS) -induced acute respiratory distress syndrome (ARDS). Patients with severe SARS-CoV-2 pneumonia (SSP) die due to poor oxygenation despite ventilatory support and different treatments including drugs with anti-viral activity, such as remdesivir, lopinavir/ritonavir, interferon beta, hydroxychloroquine; and/or anti-inflammatory drugs, such as corticosteroids, azithromycin and low molecular weight heparin amongst other [2] [3] [4] [5] . However, clinical and pathological studies of SARS-CoV-2 disease indicate that a systemic cytokine storm due to macrophage activation may be the leading cause of death in the vast majority of patients, usually occurring two to four weeks after primary infection [14] [22] [23] .	./cache/cord-300774-5mrkmctl.txt	./txt/cord-300774-5mrkmctl.txt